Treading carefully in de-escalation for bone-targeted agents - is less more, after all?

Eur J Cancer. 2021 Jan:142:141-142. doi: 10.1016/j.ejca.2020.09.019. Epub 2020 Oct 31.

Authors

Anna Patrikidou¹, Richard Cathomas²

Affiliations

¹ UCL Cancer Institute & University College London Hospital, Sarah Cannon Research Institute, 93 Harley Street, W1G 6AD London, UK. Electronic address: anna.patrikidou@sarahcannonresearch.co.uk.
² Department of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland. Electronic address: richard.cathomas@ksgr.ch.

PMID: 33143995
DOI: 10.1016/j.ejca.2020.09.019

No abstract available

Publication types

Editorial
Comment

MeSH terms

Bone Neoplasms* / drug therapy
Breast Neoplasms*
Humans
Male
Prostatic Neoplasms, Castration-Resistant*